GlassScriptPhysician profile
Joanna Lee
NPI 1235428475
$1,617.45
in general payments reported to CMS, 2019-2025
29 companies · $33.41 in 2025
The $33.41 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.79 · 2022: $567 · 2023: $837 · 2024: $163 · 2025: $33.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $204.21 | 2022-2023 | Lynparza, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $135.39 | 2022-2023 | Ninlaro, Vpriv |
| Dilon Technologies, INC. | $108.24 | 2024 | Hemoblast Bellows |
| Seagen INC. | $86.96 | 2022-2023 | Padcev |
| Janssen Biotech, INC. | $84.25 | 2022-2023 | Erleada, Rybrevant |
| Sobi, INC | $75.83 | 2022-2023 | |
| Amgen INC. | $71.76 | 2022-2023 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $69.15 | 2022-2023 | Keytruda |
| Taiho Oncology, INC. | $64.23 | 2022-2023 | |
| Pfizer INC. | $63.75 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $61.94 | 2023 | Libtayo |
| Exelixis INC. | $58.77 | 2022-2025 | Cabometyx |
| Incyte Corporation | $52.22 | 2022-2023 | Monjuvi |
| Daiichi Sankyo INC. | $51.21 | 2023 | Enhertu |
| Tactile Systems Technology INC | $49.25 | 2023 | Flexitouch Plus, Entre Plus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $48.87 | 2022 | |
| Eisai INC. | $45.93 | 2022 | |
| Merit Medical Systems INC | $38.94 | 2022 | |
| Sumitomo Pharma America, INC. | $31.18 | 2023 | Orgovyx |
| Blueprint Medicines Corporation | $29.08 | 2023 | Ayvakit |
| Lilly USA, LLC | $28.06 | 2023 | Verzenio, Retevmo |
| Puma Biotechnology, INC. | $25.04 | 2023 | |
| Morphosys, US INC. | $24.46 | 2023 | Monjuvi |
| Emd Serono, INC. | $23.43 | 2023 | Bavencio |
| Myriad Genetic Laboratories, INC. | $22.24 | 2023 | Precisetumor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.79 | 2021 | |
| Dexcom, INC. | $16.54 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.89 | 2023 | |
| Foundation Medicine, INC. | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.